VCB-1204

N/A

Report date: 2025/06/30 17:21:56

Base Information

Drug NameVCB-1204

Drug Alias NameVCB-1204

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionProgrammed death-ligand 1 modulatorsEphrin type-A receptor 2 modulatorsT lymphocyte replacements

TargetsProgrammed death-ligand 1Ephrin type-A receptor 2

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVaxcellBio Inc

China Registration ClassN/A

Develop Information

Active CompaniesVaxcellBio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A